• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄、肿瘤大小和分级可预测偶然诊断的前列腺癌的预后。

Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate.

作者信息

Goodman C M, Busuttil A, Chisholm G D

机构信息

University Department of Surgery/Urology, Western General Hospital, Edinburgh.

出版信息

Br J Urol. 1988 Dec;62(6):576-80. doi: 10.1111/j.1464-410x.1988.tb04429.x.

DOI:10.1111/j.1464-410x.1988.tb04429.x
PMID:3219513
Abstract

Of 403 consecutive cases of prostatic carcinoma 69 were diagnosed incidentally and were managed with a deferred treatment policy. The mean age at diagnosis was 74 years and mean follow-up was 42 months. Retrospective analysis confirmed that many such patients die of intercurrent disease before symptomatic tumour progression. However, patients aged 70 years or less at diagnosis with diffuse, high grade disease were shown to be at greater risk of symptomatic tumour progression. In this study 60% progressed to skeletal metastases within 3 years. Deferral of treatment in such patients appears inappropriate.

摘要

在403例连续的前列腺癌病例中,69例是偶然诊断出来的,并采用了延迟治疗策略。诊断时的平均年龄为74岁,平均随访时间为42个月。回顾性分析证实,许多此类患者在有症状的肿瘤进展之前死于并发疾病。然而,诊断时年龄在70岁及以下且患有弥漫性、高级别疾病的患者,有症状的肿瘤进展风险更高。在本研究中,60%的患者在3年内进展为骨转移。对这些患者延迟治疗似乎不合适。

相似文献

1
Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate.年龄、肿瘤大小和分级可预测偶然诊断的前列腺癌的预后。
Br J Urol. 1988 Dec;62(6):576-80. doi: 10.1111/j.1464-410x.1988.tb04429.x.
2
Incidental carcinoma of the prostate: selection for deferred treatment.前列腺偶发癌:延迟治疗的选择
Br J Urol. 1983 Dec;55(6):733-6. doi: 10.1111/j.1464-410x.1983.tb03415.x.
3
Deferred treatment for prostate cancer.前列腺癌的延迟治疗。
Br J Urol. 1988 Sep;62(3):249-53. doi: 10.1111/j.1464-410x.1988.tb04328.x.
4
[Onset of and survival in adenocarcinoma of the prostate. Analysis of 48 consecutive cases studied over 10 years].[前列腺腺癌的发病及生存情况。对连续48例患者进行10年研究的分析]
Arch Esp Urol. 1989;42 Suppl 2:117-23.
5
Deferred treatment in clinically localised prostatic carcinoma.临床局限性前列腺癌的延迟治疗
Br J Urol. 1992 Feb;69(2):183-7. doi: 10.1111/j.1464-410x.1992.tb15493.x.
6
[Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].[前列腺腺癌在诊断时发生转移的演变及预后因素]
Actas Urol Esp. 1997 Sep;21(8):724-36.
7
Incidental carcinoma of the prostate: treatment selection by second-look TURP.前列腺偶发癌:经二次经尿道前列腺切除术进行治疗选择
Br J Urol. 1984 Dec;56(6):682-6. doi: 10.1111/j.1464-410x.1984.tb06146.x.
8
Deferred treatment of low grade stage T3 prostate cancer without distant metastases.对无远处转移的低级别T3期前列腺癌进行延迟治疗。
J Urol. 1993 Feb;149(2):326-8; discussion 328-9. doi: 10.1016/s0022-5347(17)36071-8.
9
The natural course of prostatic carcinoma in relation to initial cytological grade.前列腺癌的自然病程与初始细胞学分级的关系
J Urol. 1988 Dec;140(6):1452-4. doi: 10.1016/s0022-5347(17)42071-4.
10
Pathological classification and follow-up of prostatic lesions initially diagnosed as "suspicious of malignancy".最初诊断为“怀疑恶性”的前列腺病变的病理分类及随访
Br J Urol. 1990 Sep;66(3):306-11. doi: 10.1111/j.1464-410x.1990.tb14933.x.

引用本文的文献

1
Prostate cancer: 2. Natural history.前列腺癌:2. 自然病史。
CMAJ. 1998 Sep 22;159(6):685-91.
2
A tribute to professor Geoffrey D Chisholm CBE ChM PPRCS Ed FRCS Eng FRCP Ed FRCPSG FRACS (Hon) FCSSA (Hon) FACS (Hon) FRSE.向杰弗里·D·奇泽姆教授致敬,他拥有大英帝国司令勋章(CBE)、医学硕士(ChM)、皇家外科医学院院士(PPRCS Ed)、英国皇家外科医学院院士(FRCS Eng)、爱丁堡皇家内科医学院院士(FRCP Ed)、格拉斯哥皇家内科及外科医学院院士(FRCPSG)、澳大利亚皇家外科学院荣誉院士(FRACS (Hon))、澳大利亚临床科学协会荣誉院士(FCSSA (Hon))、美国外科学院荣誉院士(FACS (Hon))、爱丁堡皇家学会院士(FRSE)。
J R Soc Med. 1996;89 Suppl 29(Suppl 29):3-12.
3
Attitude of African-Americans regarding prostate cancer clinical trials.
非裔美国人对前列腺癌临床试验的态度。
J Community Health. 1996 Apr;21(2):77-87. doi: 10.1007/BF01682300.
4
Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.预防。有多大危害?有多大益处?2. 确定益处临床意义时的十个潜在陷阱。
CMAJ. 1996 Jun 15;154(12):1837-43.
5
Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population.在随机选择的人群中通过直肠指检筛查前列腺癌。
BMJ. 1990 Apr 21;300(6731):1041-4. doi: 10.1136/bmj.300.6731.1041.
6
Measures of mortality in prostatic cancer.前列腺癌的死亡率指标。
Br J Cancer. 1990 Mar;61(3):465-8. doi: 10.1038/bjc.1990.102.
7
Prognostic variables in patients with prostate cancer: influence of blood group ABO (H), the Rhesus system, age, differentiation, tumour stage and metastases.前列腺癌患者的预后变量:ABO(H)血型系统、恒河猴血型系统、年龄、分化程度、肿瘤分期及转移的影响。
Int Urol Nephrol. 1992;24(4):417-23. doi: 10.1007/BF02550636.